This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EIDX Eidos Therapeutics (EIDX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Eidos Therapeutics Stock (NASDAQ:EIDX) 30 days 90 days 365 days Advanced Chart Remove Ads Get Eidos Therapeutics alerts:Sign Up Key Stats Today's Range$122.21▼$122.2150-Day Range$120.98▼$128.5152-Week Range$28.39▼$132.54VolumeN/AAverage Volume128,113 shsMarket Capitalization$4.75 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.Read More… Remove Ads Receive EIDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eidos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address EIDX Stock News HeadlinesEidos-Montreal lays off staff, citing inability to transfer them to new projectsMarch 31 at 10:27 PM | venturebeat.comTomb Raider Developer Eidos Montreal Hit With LayoffsMarch 31 at 10:27 PM | msn.comTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.April 2, 2025 | American Alternative (Ad)Eidos Montreal lays off more employees: 'We don’t have the capacity to entirely reallocate them to our other ongoing projects'March 31 at 10:27 PM | msn.comNext Deus Ex game seemingly canceled as Eidos Montreal is affected by layoffsNovember 3, 2024 | msn.comStellar Blade: How To Drain Water In Eidos 7 (Oblivion Side Quest)May 7, 2024 | msn.comStellar Blade: How to Solve Monorail Puzzle on Eidos 7April 26, 2024 | msn.comThe Anglo File: Game Over for Board Lapses at EidosFebruary 3, 2024 | thestreet.comSee More Headlines EIDX Stock Analysis - Frequently Asked Questions How were Eidos Therapeutics' earnings last quarter? Eidos Therapeutics, Inc. (NASDAQ:EIDX) released its quarterly earnings results on Thursday, October, 29th. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by $0.08. The business had revenue of $0.13 million for the quarter. When did Eidos Therapeutics IPO? Eidos Therapeutics (EIDX) raised $101 million in an initial public offering (IPO) on Wednesday, June 20th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Barclays was co-manager. What other stocks do shareholders of Eidos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eidos Therapeutics investors own include Bristol-Myers Squibb (BMY), CRISPR Therapeutics (CRSP), Exelixis (EXEL), NVIDIA (NVDA), Micron Technology (MU), Axsome Therapeutics (AXSM) and Occidental Petroleum (OXY). Company Calendar Last Earnings10/29/2020Today4/02/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:EIDX CIKN/A Webwww.eidostx.com Phone415-887-1471FaxN/AEmployees70Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,830,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-65.21% Return on Assets-53.04% Debt Debt-to-Equity Ratio0.14 Current Ratio11.10 Quick Ratio11.10 Sales & Book Value Annual Sales$26.69 million Price / Sales177.99 Cash FlowN/A Price / Cash FlowN/A Book Value$4.57 per share Price / Book26.74Miscellaneous Outstanding Shares38,873,000Free FloatN/AMarket Cap$4.75 billion OptionableNot Optionable Beta-0.16 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:EIDX) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eidos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eidos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.